Early Outcomes of Flebogrif^®, a Mechanochemical Ablation Technique, for Treating Chronic Venous Disorders

Chronic venous diorder Mechanochemical ablation FlebogrifObjective Flebogrif is a new mechanochemical ablation (MOCA) technique for treating chronic venous disorders (CVD), with limited studies available.This study provides early clinical outcomes from its use in South Korea.Methods A retrospective analysis was conducted on 55 patients treated with Flebogrif at a Charm Vascular Clinic in Seoul.Mechanical injury combined with foam sclerosant (2% STS and CO 2 ) was applied to 113 saphenous veins.Primary outcomes were anatomical success at 1 and 3 months, with secondary outcomes included adverse events, pain scores, rVCSS score, CIVIQ14 score, time to return to normal activities and foam sclerosant dosages. ResultsThe anatomical success rate were analyzed as 97.3% at 1 month and 96.9% at 3 months.Adverse events were mild, with no occurrences of severe events such as paresthesia or deep vein thrombosis (DVT).The mean time returned to normal activities was 1.070.42days.Notably, Flebogrif allowed treatment of multiple veins without increased risk, averaging a foam sclerosant volume of 15.855.71cc per procedure.rVCSS and CIVIQ14 scores showed a statistically significant decrease from the initial scores.Conclusion Flebogrif shows promise as an effective and safe treatment for CVD, achieving comparable results to other methods with potential cost benefits.Further studies are recommended for validation.